1. Retinoic acid receptor alpha mediates growth inhibition by retinoids in human colon carcinoma HT29 cells.
- Author
-
Nicke B, Kaiser A, Wiedenmann B, Riecken EO, and Rosewicz S
- Subjects
- Benzoates pharmacology, Cell Differentiation drug effects, Gene Expression, Humans, Isotretinoin pharmacology, RNA, Messenger analysis, Receptors, Retinoic Acid antagonists & inhibitors, Receptors, Retinoic Acid genetics, Tetrahydronaphthalenes pharmacology, Transcriptional Activation, Tretinoin pharmacology, Antineoplastic Agents pharmacology, Cell Division drug effects, HT29 Cells pathology, Receptors, Retinoic Acid physiology, Retinoids pharmacology
- Abstract
Although retinoids have been suggested to inhibit chemically induced colon carcinogenesis, the molecular mechanisms underlying retinoid-mediated growth regulation in colon carcinoma cells are unknown. Therefore, we investigated the biological effects of retinoids on growth in HT29 colon carcinoma cells. All-trans retinoic acid (ATRA) treatment of HT29 cells resulted in a profound inhibition of anchorage-independent growth without biochemical or morphological evidence for induction of differentiation. Treatment with the selective RARalpha agonist Ro 40-6055 completely mimicked the effects of ATRA on growth and transactivation of a betaRAREx2-luciferase reporter construct, while RARbeta- and gamma-specific analogues were ineffective. Furthermore, ATRA-regulated growth and transactivation could be completely blocked by a RARalpha-selective receptor antagonist. Thus, ATRA potently inhibits anchorage-independent growth in HT29 cells and this effect is mainly if not exclusively mediated by the retinoic acid receptor alpha., (Copyright 1999 Academic Press.)
- Published
- 1999
- Full Text
- View/download PDF